Prostate Cancer

Latest News

FDA approved - wladimir1804 - AdobeStock_408414612.
Darolutamide Gains FDA Approval for Metastatic Castration-Sensitive Prostate Cancer

June 3rd 2025

Darolutamide (Nubeqa) is granted FDA approval for metastatic castration-sensitive prostate cancer, enhancing survival and quality of life for patients.

Prostate cancer awareness | Image Credit: ActionGP - stock.adobe.com
New Evidence Links Arthritis to Increased Prostate Cancer Risk

May 9th 2025

ADT Wordcloud | Image Credit: © sharafmaksumov-stock.adobe.com
The Impact of ADT for Prostate Cancer on Survival and Patient Well-Being

February 14th 2025

Matthew Nielsen, MD
Using Active Surveillance to Spare Men From Unneeded Prostate Cancer Treatment

August 31st 2024

Black male patient speaking with doctor | Image credit: Clayton D/peopleimages.com - stock.adobe.com
Dr Jun Gong: Improved Access Closes the Gaps Between Black, White Men With Prostate Cancer

February 18th 2024

Continuing Medical Education
View All
July 4th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
July 4th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Paper with prostate cancer and light blue ribbon: © Vitalii Vodolazskyi - stock.adobe.com
May 9th 2023

Extended PLND Marginally Reduces Recurrence Risk in High-Risk Patients Undergoing Radical Prostatectomy

Jared Kaltwasser
No benefit was found in low-risk patients who underwent pelvic lymph node dissection (PLND).
Certain Comorbidities May Predict Cardiovascular Event Risk After ADT for Prostate Cancer
May 5th 2023

Certain Comorbidities May Predict Cardiovascular Event Risk After ADT for Prostate Cancer

Rose McNulty
The presence of certain comorbidities prior to androgen deprivation therapy (ADT) for prostate cancer may be associated with a greater risk of cardiovascular events after starting ADT, recent research found.
Doctor and Patient Talking
May 4th 2023

Patients With Prostate Cancer Most Concerned With ADT Cost, Delivery Method

Rose McNulty
A cross-sectional survey of patient preferences found that the out-of-pocket cost of treatment was the most impactful attribute for patients when choosing an androgen deprivation therapy (ADTs) for their prostate cancer.
Study Suggests Use of Active Surveillance for Prostate Cancer Is Increasing
April 21st 2023

Study Suggests Use of Active Surveillance for Prostate Cancer Is Increasing

Rose McNulty
The use of active surveillance for indolent prostate cancer cases continues to rise in the United States, but rates of use are lower in minority groups, low-income groups, and patients in rural areas, a recent study found.
Equity Diversity Inclusion Fairness Equality Words 3d Illustration: © iQoncept - stock.adobe.com
April 12th 2023

Review Highlights Gaps in Equity-Focused Cancer Care

Gianna Melillo
Reducing health care disparities may require shifting from providing equal care to providing equitable care.
Image of prostate cancer
April 4th 2023

Relugolix Shows Safety, Efficacy With and Without Concomitant Prostate Cancer Therapy

Rose McNulty
Treatment with relugolix and concomitant therapies for prostate cancer showed similar safety and efficacy to relugolix alone in a recent study.
Radiotherapy Method Impacts Survival, Risk of Metastases in Prostate Cancer
March 24th 2023

Radiotherapy Method Impacts Survival, Risk of Metastases in Prostate Cancer

Rose McNulty
Patients with prostate cancer who were treated with brachytherapy boost showed improved survival compared with those treated with external beam radiotherapy in a recent study.
Prostate Cancer Deaths in PSA-Detected Disease Remained Low at 15 Years
March 17th 2023

Prostate Cancer Deaths in PSA-Detected Disease Remained Low at 15 Years

Rose McNulty
Extended follow-up data from the ProtecT trial highlight the importance of weighing the risks associated with radical treatment versus active surveillance for newly diagnosed localized prostate cancer.
NCCN logo
March 10th 2023

Study of South African Males With Prostate Cancer Reveals Limits of Current Germline Testing

Mary Caffrey
The findings, published in the Journal of the National Comprehensive Cancer Network, add to the evidence that the shift to precision medicine is built on data that have not included sufficient numbers of patients of color.
Image of a discussion about prostate cancer: kenchiro168 - stock.adobe.com
March 6th 2023

Polygenic Risk Scores Predict Cancer Cases, but Not Aggressiveness in Prostate Cancer

Jared Kaltwasser
The new report found polygenic risk scores likely will not help identify patients at highest risk.
Doctor meeting with patient
March 2nd 2023

Study Shows Increased Rates of Active Surveillance for Prostate Cancer, but Still Room for Improvement

Rose McNulty
Rates of active surveillance for low-risk prostate cancer have improved nationally but vary locally and remain subpar overall, according to findings from a study published in JAMA Network Open.
Image of biomarker analysis
February 27th 2023

Elevated C-Reactive Protein Tied to Lower Survival Rates in Prostate Cancer

Jared Kaltwasser
Overall survival, cancer-specific survival and progression-free survival were all negatively affected by elevated C-reactive protein levels, this study found.
Study Characterizes Real-World Use of Relugolix in Combination With Other Prostate Cancer Therapies
February 19th 2023

Study Characterizes Real-World Use of Relugolix in Combination With Other Prostate Cancer Therapies

Rose McNulty
Relugolix was frequently used in combination with other medications for prostate cancer in patients both new to androgen-deprivation therapy and continuing androgen-deprivation therapy in a real-world study.
Image of genetic coding
February 14th 2023

Links Between Ancestry, Immunogenomic Landscape Investigated in Prostate Cancer

Jared Kaltwasser
The study found 143 loci where somatic copy numbers were varied based on genetic ancestry.
Hyaluronic Acid Spacer May Reduce Rectal Dosimetry, GI Toxicity From Prostate Cancer Treatment
February 9th 2023

Hyaluronic Acid Spacer May Reduce Rectal Dosimetry, GI Toxicity From Prostate Cancer Treatment

Rose McNulty
A randomized controlled trial found that the use of a rectal spacer may help mitigate the gastrointestinal (GI) toxicity associated with hypofractionated radiation therapy for prostate cancer.
Image of blood samples in test tubes
February 8th 2023

New Prostate Cancer Screening Method Could Reduce Risk of Overdiagnosis

Jared Kaltwasser
The method had high rates of sensitivity and specificity, although its sensitivity was somewhat lower in cases of localized prostate cancer.
Blood test
February 4th 2023

Novel Assay Detects and Characterizes Even Microscopic Prostate Cancers

Rose McNulty
A novel test developed at Cedars-Sinai Medical Center was able to detect and characterize even microscopic amounts of prostate cancers and could potentially help individualize treatment in the clinical setting.
International Panel Forms Consensus Best Practices for Active Surveillance in Prostate Cancer
February 1st 2023

International Panel Forms Consensus Best Practices for Active Surveillance in Prostate Cancer

Rose McNulty
Health care expert and lived experience panels came to a consensus on several aspects that should be considered in the decision to offer and continue active surveillance for prostate cancer.
Image of genetic analysis
January 26th 2023

CRISPR Knockout Identifies New Biomarkers for PARP Inhibitor Resistance in Prostate Cancer

Jared Kaltwasser
The report also suggests that ataxia telangiectasia and Rad3-related protein inhibition could be a valuable tool to overcome resistance.
Medical image
January 23rd 2023

Route Does Not Impact Diagnostic Accuracy of Micro-Ultrasound Targeted Prostate Biopsies, Study Finds

Jared Kaltwasser
The report suggests that high-resolution micro-ultrasound could help identify clinically significant lesions that would be missed with conventional MRI.
Image of prostate cancer
January 14th 2023

Risk Prediction for Risk Mitigation in Prostate Cancer Explored in New Study

Jaime Rosenberg
The importance of identifying rare pathogenic mutations and genetic risk score among patients was explored in this new analysis, with goals that included reducing mortality and early disease detection.
paper cutout of people of different races
January 13th 2023

Social Determinants of Health Linked With Varying Prostate Cancer Outcomes by Race

Hayden E. Klein
A meta-analysis supported that Black men have similar or better prostate cancer outcomes compared with White men when health care access is equal and treatment is standardized for all patients.
Latest ACS Cancer Statistics Report Highlights Alarming Trends, Disparities in Prostate Cancer
January 12th 2023

Latest ACS Cancer Statistics Report Highlights Alarming Trends, Disparities in Prostate Cancer

Rose McNulty
Following the release of its 2023 report on cancer statistics, the American Cancer Society announced a new initiative to improve prostate cancer outcomes and reduce disparities.
FDA Approves Darolutamide Combo for Metastatic Hormone-Sensitive Prostate Cancer
August 9th 2022

FDA Approves Darolutamide Combo for Metastatic Hormone-Sensitive Prostate Cancer

AJMC Staff
Darolutamide, sold as Nubeqa, is an androgen receptor inhibitor, which works to limit prostate cell growth by preventing the binding of hormones, or androgens, to proteins known as androgen receptors.
Expert on prostate cancer
March 23rd 2022

Impact of CVD Risk on Cost of Care in Prostate Cancer

John L. Fox, MD, MHA Bhavesh Shah, RPh, BCOP Maria Lopes, MD, MS
Shared insight on the impact that cardiovascular disease has on cost of care in prostate cancer.
Expert on prostate cancer
March 16th 2022

Prostate Cancer and CVD: Professional Society Guidelines

John L. Fox, MD, MHA Bhavesh Shah, RPh, BCOP Maria Lopes, MD, MS
Experts consider available professional society guidelines on prostate cancer and cardiovascular disease management.
Expert on prostate cancer
March 16th 2022

Prostate Cancer: Identifying Patients at Risk for CVD

John L. Fox, MD, MHA Bhavesh Shah, RPh, BCOP Maria Lopes, MD, MS
A brief review of factors that may put patients with prostate cancer at increased risk for developing cardiovascular disease.
DNA.
March 10th 2022

Age, Education Level Shown to Influence Genomic Profiling Adherence in Patients With Metastatic Genitourinary Cancers

Matthew Gavidia
Reasons for pursuing genomic profiling among patients with advanced bladder, renal, and prostate cancers included guiding treatment and improving treatment response, in which age and education level were found to significantly influence shared decision-making.
Expert on prostate cancer
March 9th 2022

CVD Risk Associated With ADT in Prostate Cancer

John L. Fox, MD, MHA Bhavesh Shah, RPh, BCOP Maria Lopes, MD, MS
Focusing on available agents in prostate cancer, experts consider how androgen deprivation therapy impacts risk of cardiovascular disease.
Expert on prostate cancer
March 9th 2022

An Overview of the Prostate Cancer Treatment Landscape

John L. Fox, MD, MHA Bhavesh Shah, RPh, BCOP Maria Lopes, MD, MS
A comprehensive review of the therapeutic classes available for patients with prostate cancer.
<1234>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo